THE BEST SIDE OF MRTX1133

The identification of KRASG12C inhibitors has reignited desire in targeting RAS proteins. This function describes the invention in the KRASG12D-specific inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively concentrating on this oncogenic variant.In a very trial involving 38 patients with Innovative pancreatic cancer, for